CLAIMS

1. A humanized antibody binding to human CD3, wherein said antibody comprises a binding region comprising a heavy chain variable (VH) region of SEQ ID NO: 6 and a light chain variable (VL) region of SEQ ID NO: 10.

2. The antibody according to claim 1, wherein the antibody is a full-length antibody.

3. The antibody according to claim 1 or 2, wherein the Fc region comprises heavy chains of an isotype selected from the group consisting of IgGl, IgG2, IgG3, and IgG4.

4. The antibody according to any one of the preceding claims, wherein said antibody comprises an Fc region comprising a first and a second immunoglobulin heavy chain, wherein in said first and second heavy chains the amino acids in the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain, are F, E, and A, respectively, and the amino acids in the positions corresponding to N297 and P331 in a human IgG1 heavy chain, are N and P, respectively, wherein the amino acid positions are numbered according to the EU numbering system.

5. The antibody according to claim 4, which comprises heavy chain constant regions of SEQ ID NO: 16.

6. The antibody according to claim 4, which comprises heavy chain constant regions of SEQ ID NO: 25.

7. The antibody according to claim 4, which comprises heavy chain constant regions of SEQ ID NO: 26.

8. A bispecific antibody comprising a first binding region of an antibody according to any one of claims 1 to 3, and a second binding region which binds a different target than said first binding region.

9. The bispecific antibody according to claim 8, wherein said antibody comprises a first and a second heavy chain.

10. The bispecific antibody according to claim 9, wherein said bispecific antibody comprises an Fc region modified according to any one of claims 4 to 7.

11. The bispecific antibody according to any one of claims 8 to 10, wherein each of said first and second heavy chain comprises at least a hinge region, a CH2 and CH3 region, wherein in said first heavy chain at least one of the amino acids in the positions corresponding to a positions selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain has been substituted, and in said second heavy chain at least one of the amino acids in the positions corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain has been substituted, and wherein said first and said second heavy chains are not substituted in the same positions.

12. The bispecific antibody according to claim 11, wherein the amino acid in the position corresponding to F405 in a human IgG1 heavy chain is L in said first heavy chain, and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain is R in said second heavy chain, or vice versa.

13. The bispecific antibody according to any of claims 9 to 12, wherein said first binding region is according to claim 1, and said second binding region binds a different target than said first binding region.

14. A nucleic acid construct encoding a heavy chain variable (VH) region of SEQ ID NO: 6 and a light chain variable (VL) region of SEQ ID NO: 10.

15. An expression vector comprising
(i) a nucleic acid sequence encoding a heavy chain sequence of a humanized antibody according to any one of claims 1 to 13; and
(ii) a nucleic acid sequence encoding a light chain sequence of a humanized

antibody according to any one of claims 1 to 13.

16. A host cell comprising an expression vector of claim 15, or an expression vector comprising a nucleic acid sequence encoding a heavy chain sequence of a humanized antibody according to any one of claims 1 to 13 and an expression vector comprising a nucleic acid sequence encoding a light chain sequence of a humanized antibody according to any one of claims 1 to 13.

17. The host cell according to claim 16, wherein said host cell is a recombinant eukaryotic, recombinant prokaryotic, or recombinant microbial host cell.

18. A composition comprising an antibody according to any one of claims 1 to 7 or a bispecific antibody according to any one of claims 8 to 13.

19. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 7 or bispecific antibody according to any one of claims 8 to 13 and a pharmaceutical acceptable carrier.

20. The antibody according to any one of claims 1 to 7, said bispecific antibody according to any one of claims 8 to 13, said composition according to claim 18, or said pharmaceutical composition according to claim 19 for use as a medicament.

21. Use of the antibody according to any one of claims 1 to 7, said bispecific antibody according to any one of claims 8 to 13, said composition according to claim 18, or said pharmaceutical composition according to claim 19, in the manufacture of a medicament for the treatment of a disease.

22. The use of the antibody, bispecific antibody, composition or pharmaceutical composition according to claim 21, wherein the disease is cancer, an infectious disease, or an autoimmune disease.

23. A method for producing an antibody according to any one of claims 1 to 7, or a bispecific antibody according to any one of claims 8 to 13, comprising the steps of

a) culturing a host cell according to claim 16 or 17; and

b) purifying said antibody from the culture media.

24. A method for detecting the presence of CD3 antigen, or a cell expressing CD3, in a sample comprising the steps of;

a) contacting the sample with an antibody according to any one of claims 1 to 7 or a bispecific antibody according to any one of claims 8 to 13, under conditions that allow for formation of a complex between said antibody or bispecific antibody and CD3; and

b) analyzing whether a complex has been formed.

25. A kit for detecting the presence of CD3 antigen, or a cell expressing CD3, in a sample comprising

i) an antibody according to any one of claims 1 to 7, or a bispecific antibody according to any one of claims 8 to 13; and

ii) instructions for use of said kit.